Lumenis has launched triLIFT 2.0, a platform combining muscle stimulation and skin treatment technologies for facial and body rejuvenation.
Lumenis Be Ltd announced the commercial launch of triLIFT 2.0, a platform designed for facial and body muscle stimulation that integrates Dynamic Muscle Stimulation technology (DMSt) and FibroBoost.
Addressing Muscle-Related Aging
The company stated that skeletal muscles lose 3–8% of their mass per decade after age 30, contributing to sagging, loss of jawline definition, and reduced firmness in areas such as the glutes and abdomen. The press release also noted that 70% of patients are seeking natural-looking results, while the increasing use of GLP-1 medications and associated rapid weight loss can result in 25–39% muscle mass loss and skin laxity.
Technology and Treatment Approach
According to Lumenis, triLIFT 2.0 uses DMSt to deliver high-intensity muscle contractions beyond voluntary exercise, targeting deeper muscle layers to improve tone and lift. Treatment protocols typically include five sessions for the face and six for the body, spaced one week apart.
Clinical findings cited in the release reported that 100% of body-treatment patients showed measurable improvement at one month, 94% achieved improvement in facial muscle tone and lifting, 68% reduction in body cellulite dimpling severity was observed after four treatments, and 90% achieved improvement in facial skin tightness.
FibroBoost and Skin Regeneration
The system also incorporates FibroBoost, which uses ultrathin electrodes measuring 150 microns and double pulse RF technology to penetrate the skin and stimulate collagen, elastin, and hyaluronic acid regeneration.
Lumenis described the approach as a combination of muscle activation followed by skin refinement using FibroBoost and tripolar RF, targeting both underlying muscle structure and surface skin.
Physician Perspective
“With triLIFT 2.0, our approach to both face and body has fundamentally changed. By simultaneously activating the muscle foundation and improving dermal quality, we see noticeable facial lifting alongside enhanced body contour, firmness, and tone. The outcomes are visible, natural-looking, and long lasting without surgery,” said Dr James Chelnis, MD, FACS, Ophthalmic Plastic and Reconstructive Surgeon and Head of Manhattan Face and Eye.
Market Position and Availability
Itay Mayer, chief commercial officer at Lumenis, said, “As we celebrate our 60th anniversary, we are proud to once again push innovation in the aesthetics industry with triLIFT 2.0—shifting the conversation from targeting only the skin to delivering deeper, more comprehensive rejuvenation that begins at the structure—the muscle—across both the face and body. We’re addressing a significant, growing market need for both practitioners and patients. triLIFT 2.0’s Dynamic Muscle Stimulation (DMSt) ushers in the next chapter of our innovation legacy and reinforces our commitment to shaping the future of aesthetics for decades to come.”
The system was presented at the 2026 American Academy of Dermatology annual meeting and is now available for aesthetic practices.
Photo: Lumenis Be Ltd
